Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 7:55 pm Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | Point72 Asset Management L.P. | 2,300,643 2.900% | -1,116,257 (-32.67%) | View |
| 2024-11-14 5:46 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | EcoR1 Capital LLC | 4,288,120 4.800% | 132,745 (+3.19%) | View |
| 2024-11-14 1:22 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | PRICE T ROWE ASSOCIATES INC | 4,944,757 6.200% | 4,944,757 (New Position) | View |
| 2024-11-12 2:26 pm Unchanged | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 6,287,655 7.850% | 0 (Unchanged) | View |
| 2024-11-08 10:52 am Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | WELLINGTON MANAGEMENT GROUP LLP | 4,459,691 5.570% | 1,214,586 (+37.43%) | View |
| 2024-11-04 11:20 am Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 6,287,655 7.850% | 2,785,203 (+79.52%) | View |
| 2024-10-17 12:47 pm Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | STATE STREET CORP STT | 2,838,484 3.600% | -725,252 (-20.35%) | View |
| 2024-03-11 3:34 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | EcoR1 Capital LLC | 4,155,375 5.300% | 4,155,375 (New Position) | View |
| 2024-03-01 8:05 pm Sale | 13D | CRINETICS PHARMACEUTICALS INC CRNX | PERCEPTIVE ADVISORS LLC | 1,488,703 1.900% | -3,844,829 (-72.09%) | View |
| 2024-02-14 6:36 pm Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | ORBIMED ADVISORS LLC | 1,667,360 2.500% | -1,529,516 (-47.84%) | View |
| 2024-02-14 4:14 pm Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | Point72 Asset Management L.P. | 3,416,900 5.100% | -311,052 (-8.34%) | View |
| 2024-02-14 4:06 pm Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | BRAIDWELL LP | 0 0.000% | -3,469,674 (Position Closed) | View |
| 2024-02-14 10:11 am Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -2,736,613 (Position Closed) | View |
| 2024-02-14 07:54 am Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | DRIEHAUS CAPITAL MANAGEMENT LLC | 5,039,477 7.540% | -585,267 (-10.41%) | View |
| 2024-02-13 5:02 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 3,502,452 5.240% | 3,502,452 (New Position) | View |
| 2024-02-09 08:50 am Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | FMR LLC | 4,043,865 6.053% | 2,160,747 (+114.74%) | View |
| 2024-02-08 10:11 am Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | WELLINGTON MANAGEMENT GROUP LLP | 3,245,105 4.860% | 440,620 (+15.71%) | View |
| 2024-01-25 4:59 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | BlackRock Inc. BLK | 5,345,114 8.000% | 1,427,625 (+36.44%) | View |
| 2024-01-24 10:28 am Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | STATE STREET CORP STT | 3,563,736 5.340% | 3,563,736 (New Position) | View |
| 2023-09-18 4:24 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | Point72 Asset Management L.P. | 3,727,952 5.600% | 3,727,952 (New Position) | View |